top of page

Unmet medical needs

Diabetes encompasses a spectrum of metabolic disorders, ranging from type 1 diabetes (T1D) to type 2 diabetes (T2D). Regardless of their diverse etiologies, late-stage diabetes depends on exogenous insulin injections due to a significant loss of insulin-producing beta cells. While insulin replacement therapy remains the cornerstone of treatment for insulin-dependent diabetes, in cases of severe beta cell loss, exogenous insulin administration alone is insufficient to maintain euglycemic and prevent complications.

 

The current last-resort treatment for diabetes is pancreas transplantation, but it faces limitations due to the scarcity of donor organs and the requirement for immunosuppression.

Emerging treatments include stem cell transplants, regeneration pharmacotherapies, and artificial pancreas systems. These approaches encounter challenges such as the risks of recurring autoimmune destruction, abnormal cell growth, off-target toxicity, temporary efficacy and suboptimal glycemic control.

             

The pursuit of safe and effective treatments for insulin-dependent diabetes remains a major challenge.

bottom of page